Policy & Regulation
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
17 November 2026 -

Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) said on Tuesday that its Japanese partner Eisai Co Ltd (TYO:4523) has presented new five-year data from the Clarity AD study and its long-term extension, showing increasing clinical benefit with continuous Leqembi treatment in early Alzheimer's disease.

The data, presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, also showed that 62% of patients treated at an earlier stage of disease, with low levels of tau, showed improvement in cognitive function and activities of daily living (CDR-SB) after five years.

Clarity AD is a global, placebo-controlled, double-blind, parallel-group, randomised Phase 3 study involving 1,795 patients with early Alzheimer's disease: 898 in the Leqembi group, receiving 10 mg/kg by intravenous infusion every two weeks, and 897 in the placebo group. Of the patients who completed the 18-month core study, 95% chose to participate in the subsequent long-term extension study. A total of 351 patients received five years of continuous treatment. The results support the importance of initiating treatment early in the course of Alzheimer's disease and continuing treatment to sustain the benefit over time.

No new safety findings were observed during five years of continuous Leqembi treatment.

Login
Username:

Password: